Support for Antimicrobial Development

Antimicrobial Development Support – De-Risking Innovation Programs

Smaltis supports biotech and pharmaceutical companies in structuring and accelerating antimicrobial development programs.

In a context of rising antimicrobial resistance and increasing regulatory expectations, we help innovators transform promising candidates into robust, decision-ready assets by generating high-quality microbiological evidence.

We contribute to:

• Early candidate screening and comparative activity profiling

• Mechanism-oriented microbiological investigations

• In vitro efficacy validation aligned with CLSI/EUCAST standards

• Resistance risk assessment and frequency of resistance studies

• Synergy and combination strategy evaluation

• Customized panels including clinical and multidrug-resistant isolates

Beyond experimental execution, Smaltis acts as a Microbiology Design Office, helping partners:

• Define scientifically sound development strategies

• Anticipate resistance-related risks

• Align microbiological studies with translational and regulatory objectives

• Structure antimicrobial work packages within collaborative R&D projects

We collaborate with both early-stage biotech companies seeking proof-of-concept validation and more advanced SMEs requiring robust, decision-ready microbiological data to support regulatory, partnering, or investment milestones.